Organon (OGN)

Women’s health is Organon’s defining segment. Its portfolio includes contraception products such as Nexplanon, a long-acting reversible contraceptive implant, and fertility medicines including Follistim. The company also markets products and technologies that address needs in areas such as pregnancy and postpartum care, including Jada, a device used to help manage certain cases of abnormal postpartum uterine bleeding when conservative treatment is appropriate.

Organon’s biosimilars business provides follow-on biologic medicines in areas such as immunology and oncology, where lower-cost alternatives to branded biologics can improve access for health systems and patients. Its established brands segment includes mature prescription medicines across multiple therapeutic categories. These products may have limited patent protection or face generic competition, but they remain important in many markets because of physician familiarity, distribution reach, and continuing patient demand.

The company’s strategy combines maintaining cash generation from established products with expanding its women’s health and biosimilars franchises. For investors, Organon is distinct from many pharmaceutical companies because it is less centred on a single blockbuster pipeline and more dependent on global execution, lifecycle management, pricing dynamics, and targeted business development in under-served areas of healthcare.